Xenon Pharmaceuticals Inc. (XENE)

Over the past six months, Xenon Pharmaceuticals' stock (XENE) has increased by 25.9%, trading at $56.44 as of May 9, 2026. In March 2026, positive Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures were reported, supporting a planned NDA submission to the FDA in Q3 2026. In Q1 2026, Xenon raised $837.6 million in net equity proceeds, increasing cash reserves to $1.34 billion. Xenon reported its Q1 2026 financial results, showing a net loss of $102.3 million, and the stock has experienced some volatility as investors question the timeline for its epilepsy drug pipeline to translate into real revenue.

Information regarding the demand seasonality for Xenon Pharmaceuticals, Inc.'s products and services is available but requires a free account to access. Therefore, specific details on demand seasonality cannot be provided in this summary.

Xenon Pharmaceuticals, Inc. (XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and commercializing therapeutics for neurological and psychiatric disorders, operating within the biotechnology and medical research sector, focusing on ion channel biology and genetics to create targeted treatments. The company's pipeline includes Azetukalner (XEN1101) in Phase 3 trials for epilepsy, XEN496 targeting KCNQ2-DEE, XEN1701 and XEN1120 in Phase 1 for pain treatment, NBI-921352 (Neurocrine) for SCN8A-DEE, XEN007 for treatment-resistant absence seizures, and FX301 (Flexion) for postoperative pain control.

Xenon Pharmaceuticals, Inc. has corporate offices in Vancouver, British Columbia, Canada, and Boston, Massachusetts, USA. The company aims to establish a strong presence in key global markets, including North America, Europe, and Asia, through strategic partnerships and regulatory approvals. Its clinical development and manufacturing are executed through global investigator networks and outsourced partners.

Xenon Pharmaceuticals' brand reputation in the past year is largely positive, driven by strong clinical trial results and analyst confidence, with a consensus "Buy" rating and an average price target of $74.50. The successful Phase 3 X-TOLE2 study results for azetukalner have significantly raised Xenon's profile, and the continued progress of its pipeline and substantial capital raise in Q1 2026 contribute to its financial strength. Despite some stock volatility, the overall brand reputation remains strong due to clinical progress and financial backing.

Xenon Pharmaceuticals, Inc. has a high level of institutional ownership, with 260 institutional owners and shareholders holding a total of 84,116,236 shares, ranging from approximately 81.48% to 95.45% of the stock. Major institutional owners include Fmr Llc, Avoro Capital Advisors LLC, and BlackRock, Inc. Insiders hold 4.07% of the stock and have sold $17,845,365.00 in company stock in the past three months.